{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:37:11Z","timestamp":1757313431544},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Older care home residents are a vulnerable group of people with atrial fibrillation (AF) at high risk of adverse health events. The Atrial Fibrillation Better Care (ABC: Avoid stroke; Better symptom management; Cardiovascular and other comorbidity management) pathway is the gold-standard approach toward integrated AF care, and pharmacists are a potential resource with regards to its\u2019 implementation. The aim of this study was to determine the feasibility of pharmacist-led medicines optimisation in care home residents, based on the ABC pathway compared to usual care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Individually randomised, prospective pilot and feasibility study of older (aged\u2009\u2265\u200965\u00a0years) care home residents with AF (ISRCTN14747952); residents randomised to ABC pathway optimised care versus usual care. The primary outcome was a description of study feasibility (resident and care home recruitment and retention). Secondary outcomes included the number and type of pharmacist medication recommendations and general practitioner (GP) implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one residents were recruited and 11 (mean age [standard deviation] 85.0 [6.5] years, 63.6% female) were randomised to receive pharmacist-led medicines optimisation. Only 3\/11 residents were adherent to all three components of the ABC pathway. Adherence was higher to \u2018A\u2019 (9\/11 residents) and \u2018B\u2019 (9\/11 residents) components compared to \u2018C\u2019 (3\/11 residents). Four ABC-specific medicines recommendations were made for three residents, and two were implemented by residents\u2019 GPs. Overall ABC adherence rates did not change after pharmacist medication review, but adherence to \u2018A\u2019 increased (from 9\/11 to 10\/11 residents). Other ABC recommendations were inappropriate given residents\u2019 co-morbidities and risk of medication-related adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The ABC pathway as a framework was feasible to implement for pharmacist medication review, but most residents\u2019 medications were already optimised. Low rates of adherence to guideline-recommended therapy were a result of active decisions not to treat after assessment of the net risk\u2013benefit.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-023-04527-4","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T06:02:24Z","timestamp":1705384944000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacist-led intervention for older people with atrial fibrillation in long-term care (PIVOTALL study): a randomised pilot and feasibility study"],"prefix":"10.1186","volume":"24","author":[{"given":"Leona A.","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asangaedem","family":"Akpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"4527_CR1","unstructured":"World Health Organization. European Health Information Gateway. Number of nursing and elderly home beds. Available from: https:\/\/gateway.euro.who.int\/en\/indicators\/hfa_491-5101-number-of-nursing-and-elderly-home-beds\/ [cited 1 Jan 2023]."},{"key":"4527_CR2","unstructured":"World Health Organization. Partnering with the EU to strengthen long-term care systems. Available from: https:\/\/www.who.int\/europe\/activities\/partnering-with-the-eu-to-strengthen-long-term-care-systems [cited 13 Nov 2023]."},{"key":"4527_CR3","unstructured":"Office for National Statistics. Care homes and estimating the self-funding population, England: 2021 to 2022. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/socialcare\/articles\/carehomesandestimatingtheselffundingpopulationengland\/2021to2022 [cited 08 Sept 2022]."},{"issue":"10","key":"4527_CR4","first-page":"e56","volume":"139","author":"J Benjamin Emelia","year":"2019","unstructured":"Benjamin Emelia J, Muntner P, Alonso A, BittencourtMarcio S, Callaway Clifton W, Carson April P, et al. Heart disease and stroke statistics\u20142019 Update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013528.","journal-title":"Circulation"},{"issue":"8","key":"4527_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949\u201353.","journal-title":"Eur Heart J"},{"key":"4527_CR6","doi-asserted-by":"crossref","unstructured":"Ritchie LA, Harrison SL, Penson PE, Akbari A, Torabi F, Hollinghurst J, et al. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003\u20132018. Age Ageing. 2022;51(12):afac252.","DOI":"10.1093\/ageing\/afac252"},{"issue":"1","key":"4527_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jgs.13200","volume":"63","author":"O Bahri","year":"2015","unstructured":"Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot J-M, et al. Underuse of Oral Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in France: Comparisons of Resident Characteristics and Physician Attitude. J Am Geriatr Soc. 2015;63(1):71\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"4527_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14:627.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"4527_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"issue":"01","key":"4527_CR10","first-page":"020","volume":"122","author":"TF Chao","year":"2021","unstructured":"Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2021;122(01):020\u201347.","journal-title":"Thromb Haemost"},{"issue":"4","key":"4527_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/joa3.12364","volume":"36","author":"P-S Yang","year":"2020","unstructured":"Yang P-S, Sung J-H, Jang E, Yu HT, Kim T-H, Lip GYH, et al. Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: a nationwide cohort study. J Arrhythm. 2020;36(4):668\u201377.","journal-title":"J Arrhythm"},{"issue":"10","key":"4527_CR12","doi-asserted-by":"publisher","first-page":"e014932","DOI":"10.1161\/JAHA.119.014932","volume":"9","author":"M Proietti","year":"2020","unstructured":"Proietti M, Romiti Giulio F, Olshansky B, Lane Deirdre A, Lip Gregory YH. Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post Hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc. 2020;9(10):e014932.","journal-title":"J Am Heart Assoc"},{"key":"4527_CR13","doi-asserted-by":"crossref","unstructured":"Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH, null n. Effects of the atrial fibrillation better care pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy: a peport from the ChiOTEAF registry. J Am Heart Assoc. 2022;11(7):e024319.","DOI":"10.1161\/JAHA.121.024319"},{"key":"4527_CR14","unstructured":"NHS England. Care home pharmacists to help cut overmedication and unnecessary hospital stays for frail older patients. 2018. Available from: https:\/\/www.england.nhs.uk\/2018\/03\/care-home-pharmacists-to-help-cut-over-medication-and-unnecessary-hospital-stays-for-frail-older-patients\/ [cited 10 Jul 2022]."},{"key":"4527_CR15","unstructured":"NHS England. Network contract directed enhanced service. Structured medication reviews and medicines optimisation: guidance. 2020. Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2020\/09\/SMR-Spec-Guidance-2020-21-FINAL-.pdf [cited 10 Jul 2022]."},{"issue":"12","key":"4527_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.amjmed.2022.07.014","volume":"135","author":"LA Ritchie","year":"2022","unstructured":"Ritchie LA, Penson PE, Akpan A, Lip GYH, Lane DA. Integrated care for atrial fibrillation management: the role of the pharmacist. Am J Med. 2022;135(12):1410\u201326.","journal-title":"Am J Med"},{"key":"4527_CR17","doi-asserted-by":"publisher","first-page":"e0150205","DOI":"10.1371\/journal.pone.0150205","volume":"11","author":"S Eldridge","year":"2016","unstructured":"Eldridge S, Lancaster G, Campbell M, Thabane L, Hopewell S, Coleman C, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS One. 2016;11:e0150205.","journal-title":"PLoS One"},{"key":"4527_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40814-016-0105-8","volume":"2","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016;2:64.","journal-title":"Pilot Feasibility Stud"},{"key":"4527_CR19","doi-asserted-by":"publisher","unstructured":"ISRCTN Registry. ISRCTN14747952: Pharmacist implementation of a treatment pathway for atrial fibrillation in care home residents. Available from: https:\/\/doi.org\/10.1186\/ISRCTN14747952 [cited 22 Aug 2021].","DOI":"10.1186\/ISRCTN14747952"},{"key":"4527_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2288-13-104","volume":"13","author":"SA Billingham","year":"2013","unstructured":"Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol. 2013;13:104.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"4527_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ, Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"7","key":"4527_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/europace\/eut395","volume":"16","author":"GJ Wynn","year":"2014","unstructured":"Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European heart rhythm association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965\u201372.","journal-title":"Europace"},{"key":"4527_CR23","doi-asserted-by":"crossref","unstructured":"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands). 1990;16(3):199-208","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"1","key":"4527_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy (Amsterdam, Netherlands). 1996;37(1):53\u201372.","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"1","key":"4527_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/CIRCEP.110.958033","volume":"4","author":"J Spertus","year":"2011","unstructured":"Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4(1):15\u201325.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"6","key":"4527_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1590\/S0104-11692009000600018","volume":"17","author":"SC Fabricio-Wehbe","year":"2009","unstructured":"Fabricio-Wehbe SC, Schiaveto FV, Vendrusculo TR, Haas VJ, Dantas RA, Rodrigues RA. Cross-cultural adaptation and validity of the \u201cEdmonton Frail Scale - EFS\u201d in a Brazilian elderly sample. Rev Lat Am Enfermagem. 2009;17(6):1043\u20139.","journal-title":"Rev Lat Am Enfermagem"},{"issue":"6","key":"4527_CR27","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1590\/0104-1169.2933.2371","volume":"21","author":"S Fabr\u00edcio-Wehbe","year":"2013","unstructured":"Fabr\u00edcio-Wehbe S, Rosset I, Haas V, Diniz M, Spadoti D, Partezani-Rodrigues R. Reproducibility of the Brazilian version of the Edmonton Frail Scale for elderly living in the community. Rev Lat Am Enfermagem. 2013;21(6):1330\u20136.","journal-title":"Rev Lat Am Enfermagem"},{"issue":"5","key":"4527_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ageing\/afl041","volume":"35","author":"DB Rolfson","year":"2006","unstructured":"Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton frail scale. Age Ageing. 2006;35(5):526\u20139.","journal-title":"Age Ageing"},{"key":"4527_CR29","doi-asserted-by":"crossref","unstructured":"Ramirez Ramirez JU, Cadena Sanabria MO, Ochoa ME. Edmonton frail scale in Colombian older people. Comparison with the fried criteria. Rev Esp Geriatr Gerontol. 2017;52(6):322\u20135.","DOI":"10.1016\/j.regg.2017.04.001"},{"key":"4527_CR30","unstructured":"Rolfson DB. Edmonton Frail Scale. 2020. Available from: https:\/\/edmontonfrailscale.org\/frailty-covid-19 [cited 11 Sep 2020]."},{"issue":"6","key":"4527_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1176\/ajp.140.6.734","volume":"140","author":"R Katzman","year":"1983","unstructured":"Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734\u20139.","journal-title":"Am J Psychiatry"},{"key":"4527_CR32","doi-asserted-by":"crossref","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","DOI":"10.1378\/chest.10-0134"},{"key":"4527_CR33","doi-asserted-by":"crossref","unstructured":"Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489\u201395.","DOI":"10.1503\/cmaj.050051"},{"key":"4527_CR34","doi-asserted-by":"crossref","unstructured":"Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353\u201360.","DOI":"10.1093\/ageing\/afw039"},{"key":"4527_CR35","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61\u20135.","journal-title":"Md State Med J"},{"issue":"4","key":"4527_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"4527_CR37","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12888-018-1907-4","volume":"18","author":"ID Maidment","year":"2018","unstructured":"Maidment ID, Damery S, Campbell N, Seare N, Fox C, Iliffe S, et al. Medication review plus person-centred care: a feasibility study of a pharmacy-health psychology dual intervention to improve care for people living with dementia. BMC Psychiatry. 2018;18(1):340.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"4527_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2753.2010.01374.x","volume":"17","author":"PS Nishtala","year":"2011","unstructured":"Nishtala PS, McLachlan AJ, Bell JS, Chen TF. A retrospective study of drug-related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners. J Eval Clin Pract. 2011;17(1):97\u2013103.","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"4527_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s41669-018-0069-0","volume":"2","author":"L Garattini","year":"2018","unstructured":"Garattini L, Padula A. Hospital Pharmacists in Europe: between warehouse and prescription pad? Pharmacoecon Open. 2018;2(3):221\u20134.","journal-title":"Pharmacoecon Open"},{"issue":"692","key":"4527_CR40","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp20X708197","volume":"70","author":"P Duncan","year":"2020","unstructured":"Duncan P, Ridd MJ, McCahon D, Guthrie B, Cabral C. Barriers and enablers to collaborative working between GPs and pharmacists: a qualitative interview study. Br J Gen Pract. 2020;70(692): e155.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"4527_CR41","first-page":"63","volume":"12","author":"LA Ritchie","year":"2023","unstructured":"Ritchie LA, Gordon AL, Penson PE, Lane DA, Akpan A. Stop and go: barriers and facilitators to care home research. J Frailty Aging. 2023;12(1):63\u20136.","journal-title":"J Frailty Aging"},{"issue":"1","key":"4527_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s13063-018-2915-x","volume":"19","author":"A Ellwood","year":"2018","unstructured":"Ellwood A, Airlie J, Cicero R, Cundill B, Ellard DR, Farrin A, et al. Recruiting care homes to a randomised controlled trial. Trials. 2018;19(1):535.","journal-title":"Trials"},{"issue":"12","key":"4527_CR43","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1111\/bcp.14101","volume":"85","author":"SWH Lee","year":"2019","unstructured":"Lee SWH, Mak VSL, Tang YW. Pharmacist services in nursing homes: a systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85(12):2668\u201388.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"4527_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/pds.855","volume":"12","author":"J Ulfvarson","year":"2003","unstructured":"Ulfvarson J, Adami J, Ullman B, Wredling R, Reilly M, von Bahr C. Randomized controlled intervention in cardiovascular drug treatment in nursing homes. Pharmacoepidemiol Drug Saf. 2003;12(7):589\u201393.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4527_CR45","first-page":"423","volume":"67","author":"C Verrue","year":"2012","unstructured":"Verrue C, Mehuys E, Boussery K, Adriaens E, Remon JP, Petrovic M. A pharmacist-conducted medication review in nursing home residents: impact on the appropriateness of prescribing. Acta Clin Belg. 2012;67(6):423\u20139.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"4527_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ageing\/aft077","volume":"43","author":"AL Gordon","year":"2014","unstructured":"Gordon AL, Franklin M, Bradshaw L, Logan P, Elliott R, Gladman JR. Health status of UK care home residents: a cohort study. Age Ageing. 2014;43(1):97\u2013103.","journal-title":"Age Ageing"},{"key":"4527_CR47","unstructured":"The International Consortium for Health Outcomes Measurement (ICHOM). Patient-centered outcome measures - older person. Available from: https:\/\/connect.ichom.org\/patient-centered-outcome-measures\/older-person\/ [cited 27 Jul 2022]."}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-04527-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-023-04527-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-04527-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T17:04:59Z","timestamp":1705424699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-023-04527-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4527"],"URL":"https:\/\/doi.org\/10.1186\/s12877-023-04527-4","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received sponsorship from the University of Liverpool (ref: UoL001537) on 05\/05\/2020. Ethical approval was obtained from Health and Care Research Wales (08\/06\/2020) and the Health Research Authority (15\/06\/2020) after favourable review by Wales Research Ethics Committee 4\u00a0(ref: 20\/WA\/0164). Informed consent was obtained following International Conference on Harmonisation Good Clinical Practice and Health Research Authority guidance. Adults with capacity were provided with a participant information sheet (PIS) and given as much time as they need to read over the information before obtaining written consent. Information provided within the PIS to covered the scenario of loss of capacity during the research. For adults without capacity, the LPA of Health and Welfare was provided with a consultee information sheet (CIS) and given as much time as they need to read over the information before obtaining a Consultee Declaration form. Information provided within the CIS to cover the scenario of regaining capacity during the research. Information sheets and consent\/declaration forms sent via post if necessary due to COVID-19.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent to participate"}},{"value":"Obtained on enrolment into research study. Information provided within the PIS and CIS explained that study results would be published in a scientific journal, but participants would not be identifiable from the published results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PEP owns four shares in AstraZeneca PLC and has received honoraria and\/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, Sanofi. GYHL has been a consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo, no fees are received personally. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 899871. DAL has received investigator-initiated educational grants from Bristol-Myers Squibb (BMS), has been a speaker for Bayer, Boehringer Ingelheim, and BMS\/Pfizer and has consulted for BMS, and Boehringer Ingelheim; LAR and AA have no competing interests to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}